Evidence map›Paper›PMID 31849321›Full record

ArticleBMC medical informatics and decision making2019

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.

Ruoqi Liu, Ping Zhang

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. An Early Adverse Drug Event Detection Approach with False Discovery Rate Control.medRxiv : the preprint server for health sciences · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ruoqi LiuDepartment of Computer Science and Engineering, The Ohio State University, 2015 Neil Ave, Columbus, 43210, Ohio, USA.
Ping ZhangDepartment of Computer Science and Engineering, The Ohio State University, 2015 Neil Ave, Columbus, 43210, Ohio, USA. zhang.10631@osu.edu.ORCID 0000-0002-4601-0779

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
NCATS NIH HHS UL1 TR002733
6 · The paper itself

Abstract

backgroundAdverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of drug safety signal detection methods play an important role in providing drug safety insights. However, existing methods require sufficient case reports to generate signals, limiting their usages for newly approved drugs with few (or even no) reports.

methodsIn this study, we propose a label propagation framework to enhance drug safety signals by combining drug chemical structures with FDA Adverse Event Reporting System (FAERS). First, we compute original drug safety signals via common signal detection algorithms. Then, we construct a drug similarity network based on chemical structures. Finally, we generate enhanced drug safety signals by propagating original signals on the drug similarity network. Our proposed framework enriches post-market safety reports with pre-clinical drug similarity network, effectively alleviating issues of insufficient cases for newly approved drugs.

resultsWe apply the label propagation framework to four popular signal detection algorithms (PRR, ROR, MGPS, BCPNN) and find that our proposed framework generates more accurate drug safety signals than the corresponding baselines. In addition, our framework identifies potential ADRs for newly approved drugs, thus paving the way for early detection of ADRs.

conclusionsThe proposed label propagation framework combines pre-clinical drug structures with post-market safety reports, generates enhanced drug safety signals, and can potentially help to accurately detect ADRs ahead of time. AVAILABILITY: The source code for this paper is available at: https://github.com/ruoqi-liu/LP-SDA.

Indexed as

Adverse Drug Reaction Reporting SystemsAlgorithmsBiomarkers, PharmacologicalDatabases, FactualDrug Evaluation, PreclinicalDrug-Related Side Effects and Adverse ReactionsHumansPharmacovigilanceProduct Surveillance, PostmarketingBiomarkers, PharmacologicalAdverse drug reactionsDrug similarityFDA Adverse Event Reporting SystemSignal Detection

Identifiers

PMID31849321
PMCPMC6918608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.